Ampreloxetine

Unassigned

New Medicines

Symptomatic neurogenic orthostatic hypotension (snOH)

Information

New molecular entity
Theravance Biopharma
Theravance Biopharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Nov 20Nov 20: PIII SEQUOIA (NCT03750552) and REDWOOD extension (NCT03829657) trials are still recruiting with estimated primary completion dates of Aug 21, and, Aug 22 respectively [5,6]

Category

Noradrenaline reuptake inhibitor
OH is very common, especially in the elderly, due to a number of underlying problems with BP control. Causes include autonomic failure, Parkinson disease, diabetes [2].
Symptomatic neurogenic orthostatic hypotension (snOH)
Oral